- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03588936
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Phase 1 Study of Nivolumab in Combination With Tocilizumab for Treatment of Patients With Relapsed Hematological Malignancies Post-allogeneic Transplant
Study Overview
Status
Intervention / Treatment
Detailed Description
Study disease: Hematologic malignancies including, but not exclusive to,acute/chronic leukemia, lymphoma, and myelodysplastic syndrome that has relapsed after allogeneic transplant.
Study Rationale: Phase 1 Safety/Dose Finding Study: To determine the safety and maximum tolerated dose of Nivolumab in combination with Tocilizumab.
Study Agent Description:
Tocilizumab is a monoclonal antibody and immunosuppressant; specifically, tocilizumab is an IL-6 receptor antagonist.
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor of T cells blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell proliferation and allowing the immune system to attack the tumor.
Number of Subjects: A maximum of 12 participants will be enrolled on this Phase 1 study.
Duration of Follow-up: Participants will be followed for up to one year post-treatment for survival and response.
Study Design: This is a 3 + 3 design. In a "3 + 3 design," three participants are initially enrolled into a given dose cohort. If there is no dose limiting toxicity (DLT) observed in any of these subjects, the trial proceeds to enroll additional subjects into the next higher dose cohort. If one subject develops a DLT at a specific dose, an additional three subjects are enrolled into that same dose cohort. Development of DLTs in more than one of six subjects in a specific dose cohort suggests that the maximum tolerated dose (MTD) has been exceeded, and further dose escalation is not pursued.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Hospital and the Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age≥18 years with hematological malignancies who have undergone allogeneic transplant for hematological malignancy and are ≥180 days post-transplant.
- Relapsed disease post-allogeneic transplant defined as follows i. Acute or Chronic Leukemia or myelodysplastic or myeloproliferative disorders or natural killer (NK) cell neoplasms: Bone marrow (BM) with ≥5% disease involvement or peripheral blood evidence of overt relapse ii. Lymphoma: BM evidence of relapsed/persistent disease or PET/CT or CT evidence of persistent/progressive lymphadenopathy consistent with active lymphoma. Active disease defined as nodal lesions ≥ 20 mm in the long axis or extranodal lesions≥10 mm in long and short axis or bone marrow involvement that is biopsy proven
- Karnofsky performance status ≥70 (See Appendix A for details)
- Creatinine Clearance≥60 ml/min
- Adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x upper limit of normal (ULN). Serum bilirubin and alkaline phosphatase ≤3x x ULN, or considered not clinically significant (e.g. Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.
- Without evidence of active acute or chronic graft versus host disease (GVHD)
- Off all immunosuppression and corticosteroids (other than replacement dose steroids defined as equivalent to a maximum of 10 mg Prednisone daily) for ≥28 days from first treatment.
- Off all disease targeted treatments for ≥10 days to first treatment day
- Able to provide written informed consent
- Women of child-bearing potential and men must agree to use adequate contraception for the duration of study participation and for 120 days after the last treatment with nivolumab.
- No FDA approved, more appropriate therapies available for disease control as determined by the treating physician
Exclusion Criteria
- Positive beta-human chorionic gonadotropin (HCG) in female of child-bearing potential
- Cluster of differentiation 3 (CD3) donor chimerism <5% within 4 weeks of starting study treatment
- Prior administration of donor lymphocyte infusion post-allogeneic transplant within the last 6 months of study treatment
- History of or active autoimmune disease, or other syndrome that requires systemic steroids.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.
- Uncontrolled or active infections on treatment
- Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.
- Presence of ≥grade 3 non-hematologic toxicities as per CTCAE version 5 from any previous treatment unless it is felt to be due to underlying disease.
Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution.
a. Minimum of 4 weeks from last dose of investigational agent
- Prior exposure to PD-1 or CTLA4 antibodies in the post-allogeneic transplant setting. Participants who received such agents pre-allogeneic transplant will NOT be excluded.
- Prior exposure to daratumumab in the post-allogeneic transplant setting within two months of start date of treatment with this investigational protocol. Participants who received this agent pre-allogeneic transplant will NOT be excluded
- Concurrent therapies targeted at disease relapse. However, previous treatments for relapsed disease are allowed.
- Concurrent active malignancy (exceptions: treated solid malignancy in >2 years' remission, treated basal or squamous cell carcinomas of the skin)
- History of Crohn's disease or ulcerative colitis
- History of demyelinating disorder
- Prior intolerance or allergy to tocilizumab
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nivolumab (0.25 mg/kg) and Tocilizumab
Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design). Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab. |
Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Other Names:
Participants will receive 2 doses of tocilizumab
Other Names:
|
Experimental: Nivolumab (0.5 mg/kg) and Tocilizumab
Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design). Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab. |
Participants will receive 2 doses of tocilizumab
Other Names:
Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum-tolerated Dose
Time Frame: Up to 4 weeks after last dose of study treatment (approximately 3 months)
|
Determine the safety and the maximum tolerated dose among two candidate doses of nivolumab in combination with tocilizumab for treatment of relapsed hematological malignancy post-allogeneic transplant.
Maximum-tolerated dose is based on the determination of dose-limiting toxicities.
|
Up to 4 weeks after last dose of study treatment (approximately 3 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rates Based on Imaging
Time Frame: End of study treatment (approximately 2 months)
|
The number of subjects with stable disease as evidenced by imaging (Diagnostic positron emission tomography (PET)-CT scans or CT of the neck, chest, abdomen, and pelvis).
|
End of study treatment (approximately 2 months)
|
Response Rates Based on Pathologic Response
Time Frame: End of study treatment (approximately 2 months)
|
The number of subjects with bone marrow response (achievement of complete response; <5% blasts; stable disease; progressive disease).
|
End of study treatment (approximately 2 months)
|
Overall Survival
Time Frame: Up to 1 year from beginning of treatment
|
The number of participants alive.
|
Up to 1 year from beginning of treatment
|
Progression-Free Survival
Time Frame: Up to 1 year from beginning of treatment
|
Determine the number of subjects alive and in remission after treatment.
|
Up to 1 year from beginning of treatment
|
Duration of response in responding participants
Time Frame: Up to 1 year from the beginning of treatment
|
Number of subjects with complete response or stable disease.
|
Up to 1 year from the beginning of treatment
|
Dose-limiting toxicities
Time Frame: Up to 4 weeks after last dose of study treatment (approximately 3 months)
|
The number of subjects with dose-limiting toxicities.
This will be measured by the number of adverse events as defined by the NCI CTCAE version 4.03 non-hematologic ≥ grade 3-5 signs/symptoms or by the development of steroid refractory grade 2-4 graft-versus-host disease or severe chronic graft-versus-host disease.
|
Up to 4 weeks after last dose of study treatment (approximately 3 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nirav Shah, MD, Medical College of Wisconsin
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Myelodysplastic Syndromes
- Hematologic Neoplasms
- Leukemia
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- PRO32525
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on Nivolumab (.25 mg/kg)
-
AbbVie (prior sponsor, Abbott)Genentech, Inc.CompletedNon-Small Cell Lung Cancer (NSCLC)United States, Canada, France, Singapore, Taiwan
-
Bristol-Myers SquibbCompletedMelanomaFrance, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
United BioPharmaNational Taiwan University Hospital; Kaohsiung Medical University Chung-Ho... and other collaboratorsCompleted
-
UBP Greater China (Shanghai) Co., LtdNot yet recruiting
-
Dana-Farber Cancer InstituteBristol-Myers SquibbRecruitingMeningiomasUnited States
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Parker Institute for Cancer ImmunotherapyBristol-Myers Squibb; Cancer Research Institute, New York CityCompletedAdvanced Metastatic Cancer | Advanced Prostate CancerUnited States
-
University of Sao Paulo General HospitalRecruitingCoronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass SurgeryBrazil
-
AO GENERIUMCompletedHereditary AngioedemaRussian Federation